Every blockbuster drug has two commercial lives. The first runs from approval to the loss of its composition-of-matter patent. The […]

The patent cliff bearing down on pharma between now and 2030 is not a scheduling problem. It is a structural

For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the post-IRA, outcomes-contingent revenue landscape. The numbers are

A drug patent is not a legal document. It is a financial instrument — one whose value fluctuates from zero

The global biopharmaceutical deal machine ran at record velocity in 2024. China’s out-licensing deal value hit an estimated $47 billion,

Every year, pharmaceutical companies forfeit billions in recoverable IP value not because their science failed, but because their patent strategy

Between 2025 and 2030, an estimated $200-300 billion in branded drug sales globally will lose patent protection. That figure covers

The average capitalized cost to develop a new drug now exceeds $2.23 billion. The effective market exclusivity that investment buys,

The loss of exclusivity for a blockbuster biologic is no longer a theoretical risk management exercise. It is a discrete,